Prognostic Factors of Lymphoma Patients after Autologous Stem Cell Transplantation

被引：0
作者：
Qian, Fenghua [1 ]
Fan, Wenxia [1 ]
Wei, Xia [1 ]
Zhu, Yan [1 ]
Fu, Gang [1 ]
Qin, Dabing [1 ]
Tian, Xiaobo [1 ]
Pei, Li [1 ]
Xu, Shuangnian [1 ]
Chen, Jieping [1 ]
Zhang, Yong [1 ]
机构：
[1] Third Mil Med Univ, Southwest Hosp, Dept Hematol, Chongqing, Peoples R China
来源：
ANNALS OF TRANSPLANTATION | 2015年 / 20卷
关键词：
Hematopoietic Stem Cell Transplantation; Lymphoma; Retrospective Studies; BONE-MARROW-TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; HIGH-DOSE THERAPY; CONDITIONING REGIMEN; AGGRESSIVE LYMPHOMA; RITUXIMAB IMPROVES; SALVAGE THERAPY; RISK; CHEMOTHERAPY; RELAPSE;
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Background: Hematopoietic stem cell transplantation (HSCT) is considered to be a cure for lymphoma. However, factors related to its prognosis remain unclear. Material/Methods: Eighty patients diagnosed with lymphoma and treated with autologous HSCT (Auto HSCT) were recruited. The primary endpoints included overall survival (OS) and progression-free survival (PFS). Results: After a median follow-up of 37.9 months, the 3-year OS was 75%. Univariate analysis showed age (P=0.020), elevated lactate dehydrogenase (LDH) (P=0.031), international prognostic index (IPI) (P=0.015), Eastern Cooperative Oncology Group (ECOG) (P=0.048), bone marrow involvement (P=0.038), and time to neutrophil recovery (P=0.043) were prognostic factors of lymphoma. Multivariate analysis revealed IPI (hazard ratio [HR] 1.60, 95% confidence interval [CI] 1.09-2.34, P=0.016) and time to neutrophil recovery (HR 2.69, 95% CI 1.02-7.07, P=0.045) were independent factors correlated with OS. Conclusions: IPI and neutrophil recovery are recommendatory predictors for lymphoma patients after Auto HSCT.
引用
收藏
页码：225 / 232
页数：8
相关论文
共 58 条
[1]   Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study [J].
Ali, Shihab ;
Olszewski, Adam J. .
LEUKEMIA & LYMPHOMA, 2014, 55 (07) :1570-1577
[2]   Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia [J].
Andrews, RG ;
Briddell, RA ;
Hill, R ;
Gough, M ;
McNiece, IK .
STEM CELLS, 1999, 17 (04) :210-218
[3]   Individual quality assessment of autografting by probability evaluation: a model estimated by analysis of graft-related end points in 204 patients with malignancies [J].
Baech, J ;
Roer, O ;
Johnsen, HE .
BONE MARROW TRANSPLANTATION, 2003, 31 (06) :453-458
[4]   The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation [J].
Bierman, PJ ;
Lynch, JC ;
Bociek, RG ;
Whalen, VL ;
Kessinger, A ;
Vose, JM ;
Armitage, JO .
ANNALS OF ONCOLOGY, 2002, 13 (09) :1370-1377
[5]  
Blay JY, 1998, BLOOD, V92, P3562
[6]   Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Molestias Onco-Hematologicas retrospective study [J].
Carella, Angelo M. ;
de Souza, Carmino A. ;
Luminari, Stefano ;
Marcheselli, Luigi ;
Chiappella, Annalisa ;
Di Rocco, Alice ;
Cesaretti, Marina ;
Rossi, Andrea ;
Rigacci, Luigi ;
Gaidano, Gianluca ;
Merli, Francesco ;
Spina, Michele ;
Stelitano, Caterina ;
Hohaus, Stefan ;
Barbui, Anna ;
Puccini, Benedetta ;
Miranda, Eliana C. ;
Guida, Annalisa ;
Federico, Massimo .
LEUKEMIA & LYMPHOMA, 2013, 54 (01) :53-57
[7]   Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis [J].
Czyz, Anna ;
Lojko-Dankowska, Anna ;
Matuszak, Magdalena ;
Dytfeld, Dominik ;
Kazmierczak, Maciej ;
Komarnicki, Mieczyslaw .
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2013, 17 (02) :200-204
[8]   NONPARAMETRIC-ESTIMATION OF LIFETIME AND DISEASE ONSET DISTRIBUTIONS FROM INCOMPLETE OBSERVATIONS [J].
DINSE, GE ;
LAGAKOS, SW .
BIOMETRICS, 1982, 38 (04) :921-932
[9]   Hodgkin's lymphoma: classification and pathogenesis [J].
Foss, HD ;
Marafioti, T ;
Stein, H .
PATHOLOGE, 2000, 21 (02) :113-123
[10]   Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial [J].
Guglielmi, C ;
Gomez, F ;
Philip, T ;
Hagenbeek, A ;
Martelli, M ;
Sebban, C ;
Milpied, N ;
Bron, D ;
Cahn, JY ;
Somers, R ;
Sonneveld, P ;
Gisselbrecht, C ;
Van der Lelie, H ;
Chauvin, F .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3264-3269
123456